Frontiers in Immunology (Jun 2022)

A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma

  • Xiaonan Zhang,
  • Xiaonan Zhang,
  • Simin Min,
  • Simin Min,
  • Yifan Yang,
  • Dushan Ding,
  • Dushan Ding,
  • Qicai Li,
  • Saisai Liu,
  • Saisai Liu,
  • Tao Tao,
  • Ming Zhang,
  • Baiqing Li,
  • Shidi Zhao,
  • Shidi Zhao,
  • Rongjing Ge,
  • Rongjing Ge,
  • Fan Yang,
  • Yan Li,
  • Xiaoyu He,
  • Xiaoxiao Ma,
  • Lian Wang,
  • Tianyu Wu,
  • Tao Wang,
  • Guowen Wang

DOI
https://doi.org/10.3389/fimmu.2022.876355
Journal volume & issue
Vol. 13

Abstract

Read online

TP53 is the most frequently mutated gene in lung adenocarcinoma (LUAD). The tumor immune microenvironment (TIM) is considered a vital factor that influences tumor progression and survival rate. The influence of TP53 mutation on TIM in LUAD has not been fully studied. Here we systematically investigated the relationship and potential mechanisms between TP53 mutation status and immune response in LUAD. We constructed an immune prognostic model (IPM) using immune associated genes, which were expressed differentially between the TP53 mutant and wild type LUAD patients. We discovered that TP53 mutations were significantly associated with 5 immune related biological processes. Thirty-six immune genes were expressed differentially between TP53 mutant and wild type LUAD patients. An IPM was constructed using 3 immune genes to differentiate the prognostic survival in LUAD. The high-risk LUAD group displayed significantly higher proportions of dendritic cell resting, T cell CD4 memory resting and mast cell resting, and significantly low proportions of dendritic cell activated, T cell CD4 memory activated, and mast cell activated. Moreover, IPM was found to be an independent clinical feature and can be used to predict immunotherapy responses. In summary, we constructed and validated an IPM using 3 immune related genes, which provides a better understanding of the mechanism from an immunological perspectives.

Keywords